TRINETRA › Sectors › Healthcare
Marksans Pharma Limited (MARKSANS) — share price, P/E and fundamentals
Marksans Pharma Limited (NSE: MARKSANS) closed at ₹306.20 on 30 Oct 2026, +72.9% over one year, against a 52-week range of ₹155.00 – ₹350.95.
In the quarter ended 30 Jun 2026 (consolidated, filed 12 Aug 2026) it reported revenue of ₹841 cr and net profit of ₹157 cr, a 18.7% net margin; revenue grew 35.6% and profit grew 169.7% year on year.
On four consecutive filed quarters its trailing P/E is 26.9; since 19 May 2025 its own P/E has ranged from 25.0 to 313.8 (median 191.9), and today's reading is higher than 8% of those 359 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 20.8%, ROCE 25.6%, debt-to-equity 0.01, Piotroski F-score 4 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 68% of 63 sector peers; PBT margin higher than 71% of 63 sector peers; ROE higher than 78% of 63 sector peers.
Key figures
| Last close | ₹306.20 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -9.2% / +61.0% / +72.9% |
| 52-week low – high | ₹155.00 – ₹350.95 |
| Market capitalisation | ₹13,876 cr |
| Trailing P/E | 26.9 |
| Price / book | 4.59 |
| EV / EBITDA | 16.3 |
| Earnings yield | 3.7% |
| TTM EPS | ₹11.40 |
| TTM net profit | ₹517 cr |
| Quarter revenue | ₹841 cr |
| Quarter net profit | ₹157 cr |
| Net margin | 18.7% |
| Revenue growth (YoY) | +35.6% |
| Profit growth (YoY) | +169.7% |
| Return on equity | 20.8% |
| ROCE | 25.6% |
| Debt / equity | 0.01 |
| Current ratio | 5.17 |
| Free cash flow | ₹328 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹58.5 cr |
Against Healthcare peers
| Metric | MARKSANS | Peer median | Percentile |
|---|---|---|---|
| Net margin | 18.69 | 12.67 | 68 |
| PBT margin | 24.57 | 17.57 | 71 |
| ROE | 20.80 | 13.86 | 78 |
| ROCE | 25.63 | 16.59 | 79 |
| Debt / equity | 0.01 | 0.11 | 28 |
| Cash conversion | 1.09 | 1.25 | 42 |
| Trailing P/E | 26.85 | 43.26 | 19 |
| P/B | 4.59 | 6.02 | 34 |
Questions
What is the P/E ratio of Marksans Pharma Limited?
Marksans Pharma Limited's trailing P/E is 26.9, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 19 May 2025 its P/E has ranged 25.0–313.8.
What were Marksans Pharma Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Marksans Pharma Limited reported revenue of ₹841 cr and net profit of ₹157 cr (consolidated), filed with the exchange on 12 Aug 2026.
What is Marksans Pharma Limited's ROE?
Return on equity is 20.8% based on the balance sheet dated 31 Mar 2026.
Does Marksans Pharma Limited have debt?
Debt-to-equity is 0.01 on the balance sheet dated 31 Mar 2026.
What is MARKSANS's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, MARKSANS traded between ₹155.00 and ₹350.95.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.